Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog covers the latest myeloma research from June-July 2026. It includes a review on light chain MGUS, with data from the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project; a USMIRC 20-year analysis of myeloma clinical trials in ClinicalTrials.gov; and more. Get the latest updates on new and ongoing myeloma clinical trials, as well as up-to-date news from CHMP-EMA and the U.S. FDA. READ THE BLOG.
On Thursday, July 23, Johnson & Johnson announced positive topline results from the randomized three-arm Phase 3 MonumenTAL-6 trial, evaluating Tecvayli® (teclistamab-cqyv) plus Talvey® (talquetamab-tgvs) and Talvey plus pomalidomide in adults with relapsed or refractory multiple myeloma (RRMM) who had received one to four prior lines of therapy, including an anti-CD38 antibody and lenalidomide. The two investigational arms were compared to investigator’s choice of standard of care as the third arm: elotuzumab, pomalidomide and dexamethasone (EPd); or pomalidomide, bortezomib and dexamethasone (PVd). LEARN MORE.
The IMF will host a Patient and Family Seminar on Friday, August 14, and Saturday, August 15, 2026, in Los Angeles at the Hilton in Universal City (555 Universal Hollywood Drive). Seating is FREE, but limited. Be sure to register today! REGISTER NOW.
An IMF Patient and Family Seminar will take place on October 2-3, 2026, in Short Hills, New Jersey. The seminar is FREE, but in-person seating is LIMITED. REGISTER NOW.
From August 18–24, 2026, intrepid cyclists — patients, care partners, and healthcare professionals — will cross Iceland’s breathtaking landscapes to raise vital funds for the International Myeloma Foundation’s mission.
